Medicine details

ImageAnset 8 ODT
NameAnset 8 ODT
DosageInjection
Generic NameOndansetron
Classes Central Nervous System Agent
5HT3 receptor Antagonist
Diseases CNS Disorder
Nausea
Vomiting
CompanyOpsonin Pharma Limited

Drug Package Details

Strength8 mg/4 ml
Storage Condition
Origin CountryBangladesh
Commercial Pack5
Price per pack150.00
Cost per pack132.00
Package unit4 ml amp
Price per unit30.00
Cost per unit26.40
Discount0
Coupon
Remarks

Ondansetron

Ondansetron is a selective serotonin 5-HT3 receptor antagonist. When serotonin binds to the 5HT3 receptors in the CNS or the peripheral vagal nerves, or both, it produces nausea and emesis. Ondansetron blocks this receptor, as a result serotonin cannot bind to the 5HT3 receptor. This prevents further signaling of emesis.

Ondansetron is indicated for the prevention of-

  • Nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin greater than or equal to 50 mg/m2.
  • Nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy
  • Nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen
  • Postoperative nausea and/or vomiting

Highly Emetogenic Cancer Chemotherapy:

  • A single 24-mg dose administered 30 minutes before the start of single-day highly emetogenic chemotherapy, including cisplatin greater than or equal to 50 mg/m2

Moderately Emetogenic Cancer Chemotherapy:

  • 8 mg administered 30 minutes before the start of chemotherapy, with a subsequent 8-mg dose 8 hours after the first dose. Then administer 8 mg twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy.

Radiotherapy:

  • For total body irradiation: 8 mg administered 1 to 2 hours before each fraction of radiotherapy each day.
  • For single high-dose fraction radiotherapy to the abdomen: 8 mg administered 1 to 2 hours before radiotherapy, with subsequent 8-mg doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy.
  • For daily fractionated radiotherapy to the abdomen: 8 mg administered 1 to 2 hours before radiotherapy, with subsequent 8-mg doses every 8 hours after the first dose for each day radiotherapy is given.

Postoperative:

  • 16 mg administered 1 hour before induction of anesthesia.

Pediatric 

  • Moderately Emetogenic Cancer Chemotherapy:
    • 12 to 17 years of age: 8 mg administered 30 minutes before the start of chemotherapy, with a subsequent 8-mg dose 4 and 8 hours after the first dose. Then administer 8 mg three times a day for 1 to 2 days after completion of chemotherapy.
    • 4 to 11 years of age: 4 mg administered 30 minutes before the start of chemotherapy, with a subsequent 4-mg dose 4 and 8 hours after the first dose. Then administer 4 mg three times a day for 1 to 2 days after completion of chemotherapy.

Dosage in Hepatic Impairment

In patients with severe hepatic impairment (Child-Pugh score of 10 or greater), do not exceed a total daily dose of 8 mg.

Administration Instructions

Place a tablet on the tongue immediately after removing from the blister. The tablet will dissolve immediately. Swallow with saliva. Water is not necessary for swallowing.

Side effects associated with ondansetron when used to prevent chemotherapy induced nausea include-

  • Headache
  • Malaise/fatigue
  • Constipation
  • Diarrhea
  • Rash
  • In patients who have previously shown hypersensitivity to other selective 5-HT3 receptor antagonists, hypersensitivity reactions such as anaphylaxis and bronchospasm have been reported.
  • Electrocardiogram (ECG) changes, including QT interval prolongation, have been observed in ondansetron patients. Furthermore, post-marketing cases of Torsade de Pointes in patients taking Ondansetron have been reported.
  • Serotonin syndrome has been reported when 5-HT3 receptor antagonists are used alone. The majority of reports have been linked to the concurrent use of serotonergic drugs (e.g., SSRIs, SNRIs, monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue). Some of the reported cases resulted in death.
  • The use of Ondansetron in patients who have had abdominal surgery or who have chemotherapy-induced nausea and vomiting may conceal a progressive ileus and/or gastric distension. Keep an eye out for decreased bowel activity, especially in patients who have risk factors for gastrointestinal obstruction.

Contraindication

  • Contraindicated in patients hypersensitive to Ondansetron r any of the components of the formulation.
  • Contraindicated in patients receiving concomitant apomorphine due to the risk of profound hypotension and loss of consciousness.